Active Ingredient(s):Pacritinib FDA Approved: * February 28, 2022 Pharm Company: *CTI BIOPHARMA CORP Category:Cancer
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic Janus kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3).
Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs.
1 Medical uses
3 Society and culture
5 External links
* May have multiple approval dates, manufacturers, or labelers.